Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ).
Shanghai Pharmaceuticals Holding has appointed senior executive Zhao Yong as the employee director on its eighth session board, following his election at the company’s employee representative meeting on February 11, 2026. Zhao, currently deputy Party secretary and vice president of the company, will serve alongside directors chosen by shareholders for the duration of the current board term.
The 53-year-old brings experience from leadership roles in the company’s biomedical, biopharmaceutical and medical instrument subsidiaries, and prior positions in Shanghai’s healthcare and government agencies. He will not receive separate director’s fees but will be remunerated under the firm’s internal system for his executive roles, underscoring that this is a governance and representation move rather than a change to the company’s compensation structure.
The most recent analyst rating on (HK:2607) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major Chinese pharmaceutical group engaged in the production, distribution and related services of medicines, medical devices and healthcare products. Listed in Hong Kong, it operates through a network of subsidiaries and innovation centers, serving hospital, clinical and broader healthcare markets across China.
Average Trading Volume: 2,427,914
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
See more insights into 2607 stock on TipRanks’ Stock Analysis page.